During the afternoon session, Bellicum Pharmaceuticals moved -9.47%, compared to -1.8% for the S&P 500.
Bellicum Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, is focused on discovering and developing novel cellular immunotherapies for the treatment of hematologic cancers and solid tumors in the United States and internationally. The company is now trading -82.8% away from its average analyst target price of $5.0 per share. The 1 analysts following the stock have set target prices ranging from $5.0 to $5.0, and on average give Bellicum Pharmaceuticals a rating of strong buy.
Over the last year, BLCM shares have gone down by -49.71%, which represents a difference of -39.65% when compared to the S&P 500. The stock's 52 week high is $2.2 per share and its 52 week low is $0.6. With its revenues sputtering out and its gross margins declining an average -222.05% annually over the last four years, Bellicum Pharmaceuticals may not have a strong enough business to reverse this trend.
| Date Reported | Revenue (k) | Cost of Revenue (k) | Gross Margin | YoY Growth |
|---|---|---|---|---|
| 2021-12-31 | $28 | $7,026 | -24992.86% | -1032.03% |
| 2020-12-31 | $731 | $16,870 | -2207.8% | -233.67% |
| 2019-12-31 | $4,214 | $32,097 | -661.68% | 72.42% |
| 2018-12-31 | $1,120 | $25,434 | -2399.46% | 83.01% |
| 2017-12-31 | $185 | $21,909 | -14122.7% | n/a |
